Philips' IQon Spectral CT receives FDA clearance

Reinforcing its commitment to enabling confident diagnosis through innovation, Royal Philips (NYSE: PHG AEX: PHIA) today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its IQon Spectral CT, presenting an entirely new approach to spectral imaging. This first-of-its kind technology adds a new dimension to Computed Tomography (CT) imaging, delivering anatomical information and offering the ability to characterize structures based on their material content within a single scan. The enhanced image quality may help improve confidence in diagnoses and deliver operational efficiency.

Due to its accessibility, speed and accuracy, CT imaging is widely used in the diagnosis of many different diseases and injuries. The additional level of spectral information in the CT exam helps clinicians identify the composition of materials in the body for further diagnostic interrogation.

"The IQon Spectral CT represents our commitment to leading a new, higher standard for medical imaging that is driven by clinical insights and focused on the patient experience," said Gene Saragnese, CEO Imaging Systems, Philips Healthcare. "Delivering an additional level of spectral information without impacting clinician workflow is vital for confident diagnoses that can significantly add value to help improve patient care."

Philips IQon Spectral CT was developed in close collaboration with clinicians and is designed to overcome some of their most immediate challenges, including workflow and image management issues. The technology can discriminate between X-ray photons of multiple high and low energies – similar to the principal behind a prism splitting white light into the rainbow of colors. Through the Spectral CT scan, clinicians can access the conventional grey-scale anatomical images, along with the spectral information within the same scan. As a result, Philips IQon Spectral CT enables real-time, retrospective data analysis, without disrupting a clinician's workflow and takes the guesswork out of multi-energy acquisitions, making it easy to use and allowing for routine spectral use.

"Spectral imaging has the potential to change the way clinicians practice radiology in the future," said Jacob Sosna, President of the Israeli Radiology Society and Chairman of the Department of Radiology at Hadassah Hebrew University Medical Center, who collaborated with Philips on the development the product. "A recent study with Philips IQon Spectral CT revealed enhanced diagnosis in up to 70 percent of cases. Using the prospective approach, we would only have access to spectral information in 20 or 25 percent, at maximum."

The IQon Spectral CT system is currently available for ordering in 36 countries. Philips will be showcasing the IQon Spectral CT at booth #6742 at the upcoming Radiological Society of North America Annual Meeting (RSNA), on November 30th through December 5th in Chicago, where visitors will be able to experience this new solution for themselves.

Source:

Royal Philips

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Philips Healthcare. (2019, June 19). Philips' IQon Spectral CT receives FDA clearance. News-Medical. Retrieved on September 28, 2021 from https://www.news-medical.net/news/20141125/Philips-IQon-Spectral-CT-receives-FDA-clearance.aspx.

  • MLA

    Philips Healthcare. "Philips' IQon Spectral CT receives FDA clearance". News-Medical. 28 September 2021. <https://www.news-medical.net/news/20141125/Philips-IQon-Spectral-CT-receives-FDA-clearance.aspx>.

  • Chicago

    Philips Healthcare. "Philips' IQon Spectral CT receives FDA clearance". News-Medical. https://www.news-medical.net/news/20141125/Philips-IQon-Spectral-CT-receives-FDA-clearance.aspx. (accessed September 28, 2021).

  • Harvard

    Philips Healthcare. 2019. Philips' IQon Spectral CT receives FDA clearance. News-Medical, viewed 28 September 2021, https://www.news-medical.net/news/20141125/Philips-IQon-Spectral-CT-receives-FDA-clearance.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Poole Hospital NHS Foundation Trust will be the first to use helium-free MR technology